By Ali Lyon The UK has become a “relatively small market” since leaving the European Union and must develop a different investment proposition from its counterparts in order to be interesting to multinational corporations, the boss of one of the world’s largest pharmaceuticals firms has said. Speaking shortly after his firm announced it “anticipates making £279m investment over three years” in the UK life sciences sector, Eli Lilly chief executive David Ricks warned that due to the UK’s independent trading position, it must prioritise “flexibility, agility and business responsiveness” if it is…